Picton Mahoney Asset Management Acquires Shares of 200,735 Pfizer Inc. $PFE

Picton Mahoney Asset Management bought a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 200,735 shares of the biopharmaceutical company’s stock, valued at approximately $5,115,000.

Other hedge funds have also made changes to their positions in the company. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $30,000. True Wealth Design LLC grew its position in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 974 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the second quarter worth $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Argus raised Pfizer to a “Buy,” giving the stock near‑term analyst momentum that can attract flows. Pfizer (NYSE:PFE) Raised to “Buy” at Argus
• Positive Sentiment: Pfizer reported progress on PF‑07328948 (kidney function) Phase 1 work — a pipeline advancement that supports longer‑term product value and upside beyond current franchises. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones (PADCEV+Keytruda Phase 3 benefits and full FDA approval for a BRAFTOVI regimen) reshape growth prospects away from COVID‑era revenues — a material strategic positive for future revenue mix. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a tangible move toward Physical AI and factory automation that could improve throughput, quality, and costs over time. Telescope Innovations Installs Second Self-Driving Lab at Pfizer, Advancing Physical AI Deployment
• Positive Sentiment: Market commentary continues to frame Pfizer as a defensive, high‑yield option (dividend yield cited as attractive), which supports demand in risk‑off environments. The Dividend Safe Harbor: 2 Stocks to Watch (PFE)
• Positive Sentiment: Analyst/market pieces highlight improving cash generation and active portfolio renewal, reinforcing a recovery narrative that could boost multiple expansion if sustained. Pfizer’s Quiet Cash Comeback Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Consensus analyst rating remains a “Hold” per a recent roundup — a signal that while sentiment is improving, broad analyst conviction is not yet uniformly bullish. Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: Industry reports on AI in pharma manufacturing note Pfizer among large firms integrating AI — a positive trend but more structural and longer‑term than an immediate earnings driver. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: NYSE floor events (bell‑ringing notices) are routine market color without company‑specific impact. NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Royal Bank Of Canada started coverage on shares of Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.05.

Pfizer Trading Up 0.1%

PFE opened at $26.61 on Thursday. The firm has a 50 day simple moving average of $26.23 and a 200 day simple moving average of $25.45. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a market cap of $151.31 billion, a price-to-earnings ratio of 19.57 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.